Martin Früh
University of Bern · 16 works · 536 citations · h-index 7
Top works
- The Desire for Hastened Death in Patients with Metastatic Cancer
- Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
- Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
- Thymoma with molecularly verified “conversion” to T lymphoblastic leukemia/lymphoma over 9 years
- EML4-ALK Variant Affects ALK Resistance Mutations
- ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
- Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
- Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)
- Contents Vol. 34, 2011
- Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
- SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB NSCLC
- 484: SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC